Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitus
Primary Uses in Diabetes and Obesity Management Originally developed for the treatment of type 2 diabetes, GLP-1 agonists have proven effective in promoting weight loss, making them valuable in obesity management as well
DPP-4 inhibitors are one of the few oral agents that are useful in patients with significant renal impairment
Direct answer: Seek medical guidance promptly because severe nausea, vomiting, prolonged fullness, abdominal pain, or major bowel changes may require testing and treatment
A total of 129,330 adverse events were reported for GLP-1 receptor agonists, and of these, 5.75% were cutaneous
The FDA has not approved this for children